BioSpace News Archive

Amyris, Inc., a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, announced that it has successfully scaled up the commercial production of Cannabigerol leveraging its industrial fermentation process capability.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference. For the Morgan Stanley Global Healthcare Conference, SI-BONE’s management is scheduled for a Fireside Chat on Tuesday, Septemb

Renowned Hospital in Turin, Italy Uses Innovative Radiation Therapy Delivery System to Expand Options for Advanced Cancer Care to More Patients

eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage crisis, today announced the appointment of Michael Curtis, Ph.D., as President of Research & Development (R&D

Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other business and operations, as well as the status of the filing of Emmaus’ Annual Report on Form 10-K for the year ended December 31, 2019

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTORTM, today announced that it has entered into a debt financing facility for up to $35 million with Oxford Finance and Silicon Valley Bank (SVB).

Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced it has received an Innovation Connections grant of A$37,508 plus Goods and Services Tax (GST), under the Australian Government’s Entreprenuers’ Programme

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced that applications to the Turkish Ministry of Health and local Ethics Committee have been submitted to obtain permission to recruit COVID-19 patients in Turkey for the Phase II trial of its lead drug, LSALT peptide (Metablok).

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced record results in its technology service revenues, demonstrating a continued pattern of improved growth for its first fiscal quarter ending June 30, 2020.

Rhino Novi Inc. (OTC Markets: RNOV) announces that it has entered into a binding agreement for the purchase of Biolife Sciences Corp. a Canadian company (“BioLife”). Biolife develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology.